Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions: SLC-391, pembrolizumab; Drug · Biological
Lead sponsor: SignalChem Lifesciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: BTX-A51, Azacitidine; Drug
Lead sponsor: Edgewood Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Houston, Texas

Conditions: Glioblastoma
Interventions: Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells; Biological
Lead sponsor: In8bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more

Conditions: Breast Cancer
Interventions: MK-0752; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Advanced Cancers
Interventions: Crizotinib, Dasatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Exosurf, Survanta; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 1992
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Solid Tumor, Adult, NSCLC, CRC
Interventions: D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Fresno, California • Orange, California • San Francisco, California + 4 more

Conditions: Wounds and Injury
Interventions: Recell, Control; Device · Procedure
Lead sponsor: Rubin, J. Peter, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Gout
Interventions: RDEA594, Placebo, Allopurinol; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more

Conditions: Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions: ANS014004 + PLB1004, ANS014004 + Osimertinib; Drug
Lead sponsor: Beijing Pearl Biotechnology Limited Liability Company; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Colorectal Cancer
Interventions: Rivoceranib, Trifluridine/Tipiracil; Drug
Lead sponsor: Elevar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more

Conditions: Hypertension
Interventions: valsartan/amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Interventions: XMT-1536 (Upifitamab Rilsodotin), Carboplatin; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: LCZ696, Olmesartan, Placebo of LCZ696, Placebo of Olmesartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 22
States / cities: Birmingham, Alabama • Fair Oaks, California • Hawaiian Gardens, California + 18 more

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Biological
Lead sponsor: Dickran Kazandjian, MD; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pneumocystis Carinii Pneumonia
Interventions: Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
Interventions: CA102N, LONSURF; Drug
Lead sponsor: Holy Stone Healthcare Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Gilbert, Arizona • Aurora, Colorado • Houston, Texas

Conditions: Neuroblastoma, Medulloblastoma, Relapse
Interventions: TPI 287; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 12 Months to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more

Conditions: Colorectal Cancer, Pancreatic Cancer
Interventions: KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, Heroin Dependence
Interventions: Buprenorphine/naloxone, pegInterferon; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Oakland, California

Search by objective public record fields.

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer

Dasatinib and Crizotinib in Advanced Cancer

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Study to Evaluate D-1553 in Subjects With Solid Tumors

Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Spray Skin Applied Over Bilayered Wound Matrix

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Allopurinol Combination Study

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1